Abbvie Inc. Common Stock (ABBV) 53.99 $ABBV
3 Reasons to Put Gilead On Your Watchlist
Cory Renauer, The Motley Fool - Motley Fool - Tue May 27, 5:30PM CDT
For a company in the middle of one of the most successful drug launches in history, Gilead Sciences has received more than its fair share of negative press. While its hepatitis C program is important, it's not the company's only opportunity. Let's...
CHMP Positive on Roche's Gazyvaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 4:30PM CDT
Roche (RHHBY) received positive news when the CHMP recommended the European Commission to approve Gazyvaro in combination with chlorambucil for the treatment of adult patients suffering from previously untreated CLL.
Biogen's Plegridy Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 12:10PM CDT
The CHMP issued a positive opinion for Biogen's (BIIB) multiple sclerosis candidate, Plegridy.
Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global
Could These Drugs Rain on the Obamacare Parade?
Keith Speights, The Motley Fool - Motley Fool - Sun May 25, 12:25PM CDT
Obamacare's biggest fans just might be the health insurance industry. Several of the major insurers have enjoyed nice stock gains since the Oct. 1, 2013 start date for the health insurance exchanges established by the Affordable Care Act. But could...
3 Wild Ways the Animal Kingdom is Advancing Medicine and Public Health
Maxx Chatsko, The Motley Fool - Motley Fool - Sun May 25, 11:01AM CDT
Most people are aware that various agricultural crops have been engineered to increase the production benefits for farmers (the benefits of future products will be more consumer-facing). However, I'll bet substantially fewer people know that the U.S....
Secondary Offering, Appointments, and Clinical Developments - Analyst Notes on HCA, Biogen Idec, WellPoint, AbbVie and Mylan
PR Newswire - Fri May 23, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding HCA Holdings Inc (NYSE: HCA), Biogen Idec Inc (NASDAQ: BIIB), WellPoint Inc (NYSE: WLP), AbbVie Inc (NYSE: ABBV) and Mylan Inc (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2836-100free.
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina
PR Newswire - Thu May 22, 7:30AM CDT
Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2807-100free.
AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C
CNW Group - Thu May 22, 6:45AM CDT
AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including patients with cirrhosis. The NDS is supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date,(1) with six Phase III studies that included more than 2,300 patients in over 25 countries.
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:30PM CDT
AbbVie Inc. (ABBV) announced that Humira has received orphan drug designation from the U.S. Food and Drug Administration.
The Bull Thesis for Pharmacyclics Into ASCO '14
at The Street - Wed May 21, 7:00AM CDT
If we get complete response rates from Imbruvica-Arzerra similar to what's being reported for Abbvie's ABT-199, that would be positive for Pharmacyclics
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis
PR Newswire - Tue May 20, 2:49PM CDT
AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical program is in Phase III development. HUMIRA is not currently approved to treat any form of uveitis.
FDA Designation for Bristol-Myers/AbbVie Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 20, 10:40AM CDT
Bristol-Myers (BMY) and AbbVie (ABBV) announced that the FDA has granted breakthrough therapy designation to elotuzumab.
Global B-Cell Chronic Lymphocytic Leukemia Therapeutics Pipeline Review H1 2014 - 13 Companies & 23 Drug Profiles
M2 - Tue May 20, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sztpvs/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Biogen Idec Inc. - rEVO Biologics - Nippon Shinyaku Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Immunomedics, Inc. - MABLife S.A.S - SBI Biotech Co., Ltd. - Neopharm Ltd. - Advancell - Vivia Biotech, S.L. - AbbVie Inc. - BioNovion B.V. - TheraMAB LLC. Drug Profiles - acadesine - bafetinib - rituximab - Allogeneic CD19CAR-TCM cells - FBTA-05 - CD19.CAR-CD28Z T Cells - CD19 Specific T Cell - GNKG-168 - ilorasertib - ONO-4059 - Allogeneic Cell Therapy Tumor-Derived Lymphocytes - Gene Modified T Cells for Leukemia - TG-20 - MAT-304 - Vivia-009 - Monoclonal Antibody Targeting APRIL - alemtuzumab biosimilar - GNKS-356 - TAB-08 - Central Memory T Cell Therapy For Cancer - 202-b - Xanthone Derivatives For Cancer - alemtuzumab biosimilar For more information visit http://www.researchandmarkets.com/research/sz...ll_chronic
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Review 2014 - 15 Companies & 18 Drug Profiles
M2 - Tue May 20, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7x97/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Celgene Corporation - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - AbbVie Inc. - SpectraMab GmbH Drug Profiles - ibrutinib - duvelisib - venetoclax - venetoclax rituximab - AT-7519 - MOR-208 - MEDI-551 - CTL-019 - afuresertib - PRT-2070 - Gene Modified T Cells for Leukemia - TH-302 - GNKG-168 - CC-292 - BMS-986016 - AZD-6738 - venetoclax obinutuzumab - Triplebody 19x16x19 For more information visit http://www.researchandmarkets.com/research/7s7x97/refractory
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell
Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX
PR Newswire - Tue May 20, 7:50AM CDT
The markets on Monday, May 19, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,511.86, up 0.12% and the NASDAQ Composite closed at 4,125.82, up 0.86%. The S&P 500 edged 0.38% higher, to finish the day at 1,885.08. The gains were broad based as seven out of ten sectors ended the session in positive. During the session gains in the Financials, Information Technology and Health Care sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Utilities and Telecommunication Services sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include AbbVie Inc. (NYSE: ABBV), Johnson Controls Inc. (NYSE: JCI), DISH Network Corporation (NASDAQ: DISH) and CEMEX S.A.B. de C.V. (NYSE: CX). Free technical research on ABBV, JCI, DISH and CX can be downloaded upon signing up at:
AbbVie to Present at 2014 UBS Global Healthcare Conference
PR Newswire - Tue May 20, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time.
Bristol-Myers Squibb and AbbVie announces receipt of US FDA breakthrough therapy designation for Elotuzumab
M2 - Tue May 20, 5:17AM CDT
Global biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV), a research-based biopharmaceutical company, on Monday announced the grant by the US Food and Drug Administration (FDA) of Breakthrough Therapy Designation for elotuzumab, an investigational humanized monoclonal antibody, for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.
3 Reasons to Put Gilead On Your Watchlist
Cory Renauer, The Motley Fool - Motley Fool - Tue May 27, 5:30PM CDT
For a company in the middle of one of the most successful drug launches in history, Gilead Sciences has received more than its fair share of negative press. While its hepatitis C program is important, it's not the company's only opportunity. Let's...
CHMP Positive on Roche's Gazyvaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 4:30PM CDT
Roche (RHHBY) received positive news when the CHMP recommended the European Commission to approve Gazyvaro in combination with chlorambucil for the treatment of adult patients suffering from previously untreated CLL.
Biogen's Plegridy Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 12:10PM CDT
The CHMP issued a positive opinion for Biogen's (BIIB) multiple sclerosis candidate, Plegridy.
Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating
M2 - Mon May 26, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6m5p4d/global) has announced the addition of the "Global Dermatological Drugs Market 2014-2018 with AbbVie, Galderma, J&J, Novartis, Stiefel Laboratories, Valeant Pharmaceuticals Dominating" report to their offering. One of the main drivers is the increasing global aging population. Aged patients have a greater number of dermatological disorders caused by thinning and loss of elasticity of the epidermis. Biologics are manufactured proteins interfering with the immune process involved in any dermatological disorders. In recent years, the enhanced understanding of the molecular basis underlying dermatological ailment led to the introduction of biological drugs, providing a new effective treatment option for dermatological disorders. Biologics emphasizes on specific aspects of the immune function that result in any illness. Along with topical treatments, the current market is crowded with biologics for dermatology. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst biologics; however, Abbott's Humira has increased its share significantly in the past year. The pipeline is also very promising with biologics and several other treatments for mild to moderate conditions. Hence, the Global Dermatological Drugs market is expected to reap large revenues with the increasing use of biologics. Further, the report states that one of the key challenges is the risk of side effects associated with dermatology drugs, which hampers the acceptance of advanced biologic drugs for the treatment of dermatology disorders. Key vendors dominating this space include - AbbVie Inc. - Galderma S.A. - Johnson & Johnson Ltd. - Novartis AG - Stiefel Laboratories Inc. - Valeant Pharmaceuticals International Inc. Other vendors mentioned in the report are - Actavis plc - Allergan Inc. - Almirall SA - Amgen Inc. - Astellas Pharma Inc. - AstraZeneca plc - Bayer AG - Bristol Myers Squibb Co. - Celgene Corp. - Eisai Co. Ltd. - Eli Lilly and Co. - Genentech Inc. - Incyte Corp. - Isotechnika Inc. - LEO Pharma A/S - Merck & Co. Inc. - Mylan Pharmaceuticals Inc. - Pfizer Inc. - UCB SA. Key questions answered in this report: - What will the market size and growth rate be in 2018? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by key vendors? - What are the strengths and weaknesses of each of these key vendors? For more information visit http://www.researchandmarkets.com/research/6m5p4d/global
Could These Drugs Rain on the Obamacare Parade?
Keith Speights, The Motley Fool - Motley Fool - Sun May 25, 12:25PM CDT
Obamacare's biggest fans just might be the health insurance industry. Several of the major insurers have enjoyed nice stock gains since the Oct. 1, 2013 start date for the health insurance exchanges established by the Affordable Care Act. But could...
3 Wild Ways the Animal Kingdom is Advancing Medicine and Public Health
Maxx Chatsko, The Motley Fool - Motley Fool - Sun May 25, 11:01AM CDT
Most people are aware that various agricultural crops have been engineered to increase the production benefits for farmers (the benefits of future products will be more consumer-facing). However, I'll bet substantially fewer people know that the U.S....
Secondary Offering, Appointments, and Clinical Developments - Analyst Notes on HCA, Biogen Idec, WellPoint, AbbVie and Mylan
PR Newswire - Fri May 23, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding HCA Holdings Inc (NYSE: HCA), Biogen Idec Inc (NASDAQ: BIIB), WellPoint Inc (NYSE: WLP), AbbVie Inc (NYSE: ABBV) and Mylan Inc (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2836-100free.
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina
PR Newswire - Thu May 22, 7:30AM CDT
Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2807-100free.
AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C
CNW Group - Thu May 22, 6:45AM CDT
AbbVie (NYSE: ABBV) filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including patients with cirrhosis. The NDS is supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date,(1) with six Phase III studies that included more than 2,300 patients in over 25 countries.
1 Breakthrough, 3 Beneficiaries: AbbVie Inc., Bristol Myers Squibb Co., and Celgene Corporation
Keith Speights, The Motley Fool - Motley Fool - Wed May 21, 5:30PM CDT
A little good news can sometimes go a long way. On Monday, Bristol-Myers Squibb and AbbVie announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for multiple myeloma drug elotuzumab. This news bodes...
AbbVie's Humira Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 21, 3:30PM CDT
AbbVie Inc. (ABBV) announced that Humira has received orphan drug designation from the U.S. Food and Drug Administration.
The Bull Thesis for Pharmacyclics Into ASCO '14
at The Street - Wed May 21, 7:00AM CDT
If we get complete response rates from Imbruvica-Arzerra similar to what's being reported for Abbvie's ABT-199, that would be positive for Pharmacyclics
AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Certain Forms of Non-infectious Uveitis
PR Newswire - Tue May 20, 2:49PM CDT
AbbVie (NYSE:ABBV) announced today that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye. AbbVie is investigating the efficacy and safety of HUMIRA for the treatment of non-infectious uveitis, and the clinical program is in Phase III development. HUMIRA is not currently approved to treat any form of uveitis.
FDA Designation for Bristol-Myers/AbbVie Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 20, 10:40AM CDT
Bristol-Myers (BMY) and AbbVie (ABBV) announced that the FDA has granted breakthrough therapy designation to elotuzumab.
Global B-Cell Chronic Lymphocytic Leukemia Therapeutics Pipeline Review H1 2014 - 13 Companies & 23 Drug Profiles
M2 - Tue May 20, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sztpvs/bcell_chronic) has announced the addition of the "B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Involved in Therapeutics Development - Biogen Idec Inc. - rEVO Biologics - Nippon Shinyaku Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Immunomedics, Inc. - MABLife S.A.S - SBI Biotech Co., Ltd. - Neopharm Ltd. - Advancell - Vivia Biotech, S.L. - AbbVie Inc. - BioNovion B.V. - TheraMAB LLC. Drug Profiles - acadesine - bafetinib - rituximab - Allogeneic CD19CAR-TCM cells - FBTA-05 - CD19.CAR-CD28Z T Cells - CD19 Specific T Cell - GNKG-168 - ilorasertib - ONO-4059 - Allogeneic Cell Therapy Tumor-Derived Lymphocytes - Gene Modified T Cells for Leukemia - TG-20 - MAT-304 - Vivia-009 - Monoclonal Antibody Targeting APRIL - alemtuzumab biosimilar - GNKS-356 - TAB-08 - Central Memory T Cell Therapy For Cancer - 202-b - Xanthone Derivatives For Cancer - alemtuzumab biosimilar For more information visit http://www.researchandmarkets.com/research/sz...ll_chronic
Global Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics Pipeline Review 2014 - 15 Companies & 18 Drug Profiles
M2 - Tue May 20, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7s7x97/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Celgene Corporation - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - SBI Biotech Co., Ltd. - AbbVie Inc. - SpectraMab GmbH Drug Profiles - ibrutinib - duvelisib - venetoclax - venetoclax rituximab - AT-7519 - MOR-208 - MEDI-551 - CTL-019 - afuresertib - PRT-2070 - Gene Modified T Cells for Leukemia - TH-302 - GNKG-168 - CC-292 - BMS-986016 - AZD-6738 - venetoclax obinutuzumab - Triplebody 19x16x19 For more information visit http://www.researchandmarkets.com/research/7s7x97/refractory
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell
Morning Analysis on Active Equities -- Research on AbbVie, Johnson Controls, DISH, and CEMEX
PR Newswire - Tue May 20, 7:50AM CDT
The markets on Monday, May 19, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,511.86, up 0.12% and the NASDAQ Composite closed at 4,125.82, up 0.86%. The S&P 500 edged 0.38% higher, to finish the day at 1,885.08. The gains were broad based as seven out of ten sectors ended the session in positive. During the session gains in the Financials, Information Technology and Health Care sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Utilities and Telecommunication Services sectors. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include AbbVie Inc. (NYSE: ABBV), Johnson Controls Inc. (NYSE: JCI), DISH Network Corporation (NASDAQ: DISH) and CEMEX S.A.B. de C.V. (NYSE: CX). Free technical research on ABBV, JCI, DISH and CX can be downloaded upon signing up at:
AbbVie to Present at 2014 UBS Global Healthcare Conference
PR Newswire - Tue May 20, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the 2014 UBS Global Healthcare Conference on Wednesday, May 21, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 9:30 a.m. Central time.
Bristol-Myers Squibb and AbbVie announces receipt of US FDA breakthrough therapy designation for Elotuzumab
M2 - Tue May 20, 5:17AM CDT
Global biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV), a research-based biopharmaceutical company, on Monday announced the grant by the US Food and Drug Administration (FDA) of Breakthrough Therapy Designation for elotuzumab, an investigational humanized monoclonal antibody, for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.
